Q3 2025 EPS Estimates for Pfizer Inc. Increased by Analyst (NYSE:PFE)

Pfizer Inc. (NYSE:PFE) – Equities research analysts at Zacks Research raised their Q3 2025 earnings estimates for shares of Pfizer in a research note issued on Wednesday, June 26th. Zacks Research analyst K. Shah now forecasts that the biopharmaceutical company will post earnings of $0.73 per share for the quarter, up from their previous estimate of $0.72. The consensus estimate for Pfizer’s current full-year earnings is $2.38 per share. Zacks Research also issued estimates for Pfizer’s FY2025 earnings at $2.61 EPS.

Several other brokerages have also recently commented on PFE. Morgan Stanley lifted their price objective on shares of Pfizer from $28.00 to $29.00 and gave the company an “equal weight” rating in a research note on Thursday, May 2nd. BMO Capital Markets restated an “outperform” rating and set a $36.00 price objective (up from $33.00) on shares of Pfizer in a research note on Thursday, May 2nd. Argus cut shares of Pfizer from a “buy” rating to a “hold” rating in a research note on Friday, March 22nd. Finally, Cantor Fitzgerald restated an “overweight” rating and set a $45.00 price objective on shares of Pfizer in a research note on Wednesday, June 26th. Nine analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $35.54.

Pfizer Stock Down 1.4 %

NYSE:PFE opened at $27.83 on Monday. The company has a current ratio of 1.05, a quick ratio of 0.78 and a debt-to-equity ratio of 0.66. Pfizer has a twelve month low of $25.20 and a twelve month high of $37.80. The company’s 50 day moving average is $27.93 and its two-hundred day moving average is $27.70. The company has a market cap of $157.70 billion, a PE ratio of -464.76, a P/E/G ratio of 1.10 and a beta of 0.69.

Pfizer (NYSE:PFE) last released its earnings results on Wednesday, May 1st. The biopharmaceutical company reported $0.82 earnings per share for the quarter, topping the consensus estimate of $0.56 by $0.26. The company had revenue of $14.88 billion for the quarter, compared to the consensus estimate of $13.87 billion. Pfizer had a negative net margin of 0.56% and a positive return on equity of 8.64%. Pfizer’s revenue was down 19.5% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $1.23 EPS.

Institutional Investors Weigh In On Pfizer

Large investors have recently modified their holdings of the business. Clifford Swan Investment Counsel LLC grew its holdings in shares of Pfizer by 4.7% during the fourth quarter. Clifford Swan Investment Counsel LLC now owns 417,070 shares of the biopharmaceutical company’s stock worth $12,007,000 after buying an additional 18,611 shares in the last quarter. Adage Capital Partners GP L.L.C. grew its holdings in shares of Pfizer by 40.5% in the third quarter. Adage Capital Partners GP L.L.C. now owns 4,739,672 shares of the biopharmaceutical company’s stock valued at $157,215,000 after purchasing an additional 1,365,295 shares during the period. LifePlan Financial LLC acquired a new position in Pfizer in the fourth quarter valued at about $255,000. Cantor Fitzgerald Investment Advisors L.P. acquired a new position in Pfizer in the fourth quarter valued at about $16,166,000. Finally, KLCM Advisors Inc. lifted its position in Pfizer by 75.0% in the fourth quarter. KLCM Advisors Inc. now owns 173,793 shares of the biopharmaceutical company’s stock valued at $5,004,000 after buying an additional 74,487 shares during the last quarter. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Pfizer Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 3rd. Investors of record on Friday, July 26th will be issued a $0.42 dividend. This represents a $1.68 annualized dividend and a yield of 6.04%. The ex-dividend date of this dividend is Thursday, July 25th. Pfizer’s payout ratio is presently -2,799.53%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.